SEC Form 4 · accession 0001179110-19-001682
Editas Medicine, Inc. · EDIT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vickesh Myer
Officer — Chief Technology Officer
Period of report
Feb 6, 2019
Accepted (ET)
Feb 8, 2019 · 7:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001650664
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $21.10 | Feb 6, 2019 | A | 48,750 | A | — | Feb 5, 2029 | Common Stock | 48,750 | 48,750 | D |
| Restricted Stock UnitsF2,F3 | — | Feb 6, 2019 | A | 8,125 | A | — | — | Common Stock | 8,125 | 8,125 | D |
Explanation of responses
- F1This option was granted on February 6, 2019 and is scheduled to vest over four years in equal monthly installments beginning on February 6, 2019 through February 6, 2023.
- F2Each restricted stock unit represents the right to receive one share of common stock of Editas Medicine, Inc.
- F3The restricted stock unit award is scheduled to vest over four years with 25% of the units vesting on February 6, 2020 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 6, 2023. Shares will be delivered to the Reporting Person when units vest.